Profese online 2018, 11(1):1-8 | DOI: 10.5507/pol.2018.001

Patients using new oral anticoagulants - results of an epidemiological study

Anna Zatloukalová1,2, Jana Janoutová3, Miroslav Homza4, Ondřej Machazcka1,2, Vladimír Janout3
1 Ústav epidemiologie a ochrany veřejného zdraví, Lékařská fakulta, Ostravská univerzita, Ostrava, Česká republika
2 Centrum epidemiologického výzkumu, Lékařská fakulta, Ostravská univerzita, Ostrava, Česká republika
3 Centrum vědy a výzkumu, Fakulta zdravotnických věd, Univerzita Palackého, Olomouc, Česká republika
4 Kardiovaskulární oddělení, Fakultní nemocnice Ostrava, Česká republika

Background: New oral anticoagulants are undoubtedly a big step forward. Their use is safer than warfarin, and there is no need for monitoring, which provides a great deal of relief especially for less-moving patients. In spite of their great advantages, especially for the optimization of treatment, the group of patients and their basics should be monitored.

Aim: The aim of the study was to find out the basic characteristics of patients, including comorbidities and other important parameters.

Methods: The data was obtained from the Benedor cardiac database in Ostrava. The selection criterion was the use of DOACs (Direct Oral Anticoagulants), i.e. the use of dabigatran, rivaroxaban or apixaban. The EpiData program was used for data processing. Data was also exported and processed in Excel, Stata and OpenEpi. The total number of respondents was 334 patients.

Results: The most prominent feature of patients was overweight and obese 55.8%. Normal weight was maintained by only 11.3% of patients. Most patients suffered from three other diseases (most often hypertension and ischemic heart disease).

Conclusion: In general, a group of patients may be characterized as polymorbid, overweight or obese. It would be appropriate to lead patients to a healthy lifestyle and thus improve their health.

Keywords: New peroral anticoagulants, dabigatran, rivaroxaban, apixaban, darexaban

Received: January 2018; Accepted: June 2018; Published: July 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zatloukalová, A., Janoutová, J., Homza, M., Machazcka, O., & Janout, V. (2018). Patients using new oral anticoagulants - results of an epidemiological study. Profese Online, 11(1), 1-8. doi: 10.5507/pol.2018.001
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article
    Czech version

    References

    1. Zatloukalová A, Janoutová J, Homza M a Janout V. New anticoagulants. Profese online. 2017;10(2):1-9. DOI: 10.5507/pol.2017.006. Available from: http://profeseonline.upol.cz/doi/10.5507/pol.2017.006.html Go to original source...
    2. Conolly SJ, Eikelboom J, Joyner C. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364(9):806-817. Go to original source... Go to PubMed...
    3. Patel MR, Mahaffey KW, Garg J. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-891. Go to original source... Go to PubMed...
    4. Granger CHB, Alexander JH, McMurray JV, et al. for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992. Go to original source... Go to PubMed...
    5. Špinar J, Vítovec J, Špinarová, L, Musil V. Profile of Czech AF 2012. Profile of atrial fibrillation patients receiving antithrombotic therapy. Cor et Vasa [online]. 2014;56(3):e207-e216 [cit. 2018-01-30]. DOI: 10.1016/j.crvasa.2014.04.001. Available from: http://linkinghub.elsevier.com/retrieve/pii/S001086501400040X Go to original source...
    6. Musil V. Rizikové faktory fibrilace síní. Kardiol Rev Int Med. 2010;12(3):131-133.
    7. Hirmerová J, Karetová D, Malý R, Musil D, Roztočil K. Akutní žilní trombóza 2014: Současný stav, prevence, diagnostiky a léčby: Doporučený postup české angiologické společnosti ČLS JEP. Česká společnost pro trombózu a hemostázu ČLS JEP [online]. 2014;1(1):1-68 [cit. 2018-01-30]. Available from: https://www.csth.cz/soubory/Zilni_tromboza_doporuceni.pdf
    8. Filipovský J. Arteriální hypertenze ve stáří. Medicina po Promoci [online]. 2017;18(2):158-163 [cit. 2018-01-30]. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=asn&an=124083809≻ope=site
    9. Bultas J, Karetová D. Výběr nemocných k léčbě NOAC - co zohlednit? Interní Med [online]. 2015;17(3):118-122 [cit. 2018-01-30]. Available from: https://www.internimedicina.cz/
    10. Souhrn údajů o přípravku ELIQUIS. The European medicines agency: Science medicines health [online]. EU: An agency of the European Union. 2015 [cit. 2018-01-30]. Available from: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf
    11. Souhrn údajů o přípravku PRADAXA. The European medicines agency: Science medicines health [online]. EU: An agency of the European Union. 2015 [cit. 2018-01-30]. Available from: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf
    12. Souhrn údajů o přípravku XARELTO. The European medicines agency: Science medicines health [online]. EU: An agency of the European Union. 2015 [cit. 2018-01-30]. Available from: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf
    13. Žejglicová K, Kratěnová J, Lustigová M, Čapková N, Kubínová R.Vybrané ukazatele zdravotního stavu české populace - výsledky studie EHES 2014. Prakt lék [online]. 2017;97(3):123-130 [cit. 2018-01-30]. Available from: http://www.prolekare.cz/prakticky-lekar-clanek/vybrane-ukazatele-zdravotniho-stavu-ceske-populace-vysledky-studie-ehes-2014-61210
    14. Cífková, R, Vaverková H, Filipovský J. a Aschermann M. Summary of the European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Cor et Vasa. 2014;56(2):e169-e189. DOI: 10.1016/j.crvasa.2014.02.009. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0010865014000265 Go to original source...
    15. Povová J, Dalecká A, Hývnarová L, Tomášková H, Ambroz P, Vařechová K, Janout V. Srovnání rizika z kouření cigaret a vodní dýmky. Prakt Lék [online]. 2015;95(3):127-130 [cit. 2018-01-30]. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=asn&an=103455492≻ope=site.

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content